Heat-killed probiotic lifted NK cell activity in trial

Probiotics are marketed heavily for "immune support", but the chain of reasoning behind that claim is usually incomplete: a strain is shown to change gut bacteria in a dish, and immune benefit is assumed. Bridging that gap requires both a human trial measuring an actual immune readout and a mechanistic account of how gut microbes could produce it. This study looked at a heat-treated version of Lactiplantibacillus plantarum LM1004 — a bacterium that is not alive when consumed — which raises the further question of whether a non-living preparation can still influence the microbiome and host immunity at all.

The researchers ran a randomised, placebo-controlled clinical trial of heat-treated L. plantarum LM1004 (HT-LM1004) lasting 8 weeks, assessing both efficacy and safety. The immune outcomes reported were natural killer (NK) cell activity and white blood cell counts, compared against the placebo group. In parallel, they used a simulated human intestinal microbiome ecosystem — a laboratory model with separate compartments representing the ascending, transverse and descending colon — to probe mechanism. Within that model they profiled microbial species diversity and richness at End and Post time points, ran metabolomics analyses, and measured short-chain fatty acid (SCFA) profiles across the different gut regions.

After 8 weeks of supplementation, NK cell activity was significantly enhanced relative to placebo, with a concurrent improvement in white blood cell counts; the authors stress both remained within the normal physiological range, framing the result as a lift in baseline immune defence rather than a correction of deficiency. In the simulated ecosystem, HT-LM1004 increased microbial species diversity in the ascending colon, followed by higher richness in the transverse and descending colon at the later time points, which the authors read as selective enrichment of low-abundance beneficial taxa. Metabolomics showed compartment-specific changes, most notably in bile acid metabolism pathways, while non-bile-acid metabolites were mostly enriched in the descending colon. SCFA profiling showed distinct, time-dependent changes across compartments rather than a single uniform shift.

The finding sits within a broader move to test heat-treated or non-viable bacterial preparations, which are easier to standardise and store than live probiotics. Pairing a human immune outcome with a compartmentalised gut model is a stronger design than either alone, because it offers a plausible route from bacteria to metabolites to host response. But the mechanistic half of the story happened in a machine, not in the trial participants, so the link between the diversity and bile acid changes and the NK cell result remains inferred rather than demonstrated. Open questions include who benefits, whether the immune shift persists beyond 8 weeks, and whether it translates into fewer illnesses.

This is a reason to think that a heat-treated bacterial preparation can register a measurable change in immune cell activity over a couple of months, which is more than many products can show. It is not evidence that anyone taking it will get ill less often — NK cell activity and white blood cell counts are laboratory markers, and the authors themselves note the values stayed inside the normal range. The commercial involvement of the strain's manufacturer and the absence of reported participant numbers in the abstract are both reasons to treat this as an early signal. Independent replication with clinical endpoints would be the thing to watch for.'